| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Niagen Bioscience, Inc. (NAGE) has 8 insiders with recent SEC Form 4 filings, including 8 buys and 2 sells. NAGE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 20.0K | $83.5K | - | |
| Dir | 20.0K | $83.5K | - | |
| Dir | 20.0K | $83.5K | - | |
| Dir | 20.0K | $83.5K | - | |
| Dir | 20.0K | $83.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 19, 2020 | Fried Robert N51 | CEO | Buy | 1,000 | $4.69 | $4,690.00 | - | |
| Nov 14, 2019 | Fried Robert N51 | CEO | Buy | 10,000 | $3.09 | $30,900.00 | +0.7% | |
| Aug 23, 2019 | Fried Robert N51 | CEO | Buy | 2,500 | $4.03 | $10,075.00 | +0.2% | |
| May 21, 2019 | Fried Robert N51 | CEO | Buy | 2,253 | $4.43 | $9,980.79 | +0.2% | |
| Mar 15, 2019 | Farr Kevin M69 | Chief Financial Officer | Buy | 6,900 | $3.85 | $26,565.00 | +23.2% | |
| Mar 15, 2019 | Fried Robert N51 | CEO | Buy | 5,000 | $3.80 | $19,000.00 | +0.4% | |
| Mar 14, 2019 | Farr Kevin M69 | Chief Financial Officer | Buy | 6,725 | $3.99 | $26,832.75 | +29.2% | |
| Mar 12, 2019 | Farr Kevin M69 | Chief Financial Officer | Buy | 7,300 | $3.62 | $26,426.00 | +46.5% | |
| Mar 11, 2019 | Block Stephen A | Director | Sale+OE | 10,000 | $3.52 | $35,200.00 | -37.5% | |
| Mar 11, 2019 | Jaksch Frank L Jr | Executive Chairman Of Board | Sale+OE | 14,390 | $3.50 | $50,365.00 | -6.1% |